Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
Galecto has announced they have completed enrollment in their Phase2b trial which will investigate GB0139 as a treatment for idiopathic pulmonary fibrosis (IPF). This trial is called GALACTIC-1. Galecto anticipates…